Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective

Bois, A. Du; Pfisterer, J.; Meier, W.; Wagner, U.

doi:10.1136/ijgc-00009577-200311001-00007

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is hopeful interest in evaluating the addition of gemcitabine to one of the most common regimens for ovarian cancer, that of taxane–platinum doublet. Reports regarding the activity of the gemcitabine/carboplatin/paclitaxel triplet appear to justify this optimism (34–36) , and the gemcitabine/paclitaxel combination is presently undergoing phase III evaluation within the 5‐arm GOG 182/ICON‐5 collaboration (37) , as well as within a separate trial run by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO), using a carboplatin/paclitaxel control (38) . However, there would also appear to be potential for developing the gemcitabine and paclitaxel doublet within a different first‐line strategy, as a non–cross‐resistant, postplatinum, consolidation regimen.…”

Section: Discussionmentioning

confidence: 99%

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

Poole¹,

Perren²,

Gawande³

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

We examined appropriate sequence, schedule, and doses of gemcitabine (G) and paclitaxel (T) in patients with persistent or recurrent epithelial ovarian cancer. Patients received a maximum of six cycles of gemcitabine on days 1 and 8 (starting 1000 mg/m(2)), and paclitaxel (starting 135 mg/m(2)) on day 8 (groups A and B) or day 1 (group C). Drug sequences (G-->T and T-->G) were tested in group A. In group A, changing sequences of gemcitabine and paclitaxel infusion were evaluated. Sequence G-->T raised grade 3 alanine transaminase in two of three patients leading to use of T-->G sequence for remainder of study. In group B, maximum tolerable dose was reached at gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2). Reducing paclitaxel to 150 mg/m(2) allowed escalation of gemcitabine to 1250 mg/m(2), but neutropenia-related treatment delays occurred. Giving paclitaxel on day 1 (group C) enabled administration of paclitaxel 175 mg/m(2) and gemcitabine 1250 mg/m(2) with minimal dose adjustments. The overall response rate was 41.0%, with 2 complete responses and 14 partial responses in 39 eligible patients. The schedule of paclitaxel 175 mg/m(2) (day 1) and gemcitabine 1250 mg/m(2) (days 1 and 8), with sequence of T-->G, appears most suitable with tolerable toxicity and promising activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

Poole¹,

Perren²,

Gawande³

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Nevertheless, PFS was superior in the TEC arm. OS analysis is still pending and is awaited at the end of 2003 ( 47 ) .…”

Section: Front‐line Treatmentmentioning

confidence: 99%

Ovarian cancer treatment: what is new

Poveda

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

Ovarian cancer is still the fourth cause of death by cancer among women and the most fatal among gynecological tumors. The purpose of this symposium is, year after year, to report and discuss the new developments in the treatment of patients with ovarian cancer, the majority of whom still present with advanced disease. It also tries to make it clear to the participants what is evidence-based and what is not. Mature data of both classic studies like GOG-111, OV-10, and more recent studies like GOG-158, AGO-OVAR-3, and the intergroup paclitaxel/epirubicin/carboplatin (TEC) versus paclitaxel/carboplatin (TC) study have been presented. Other current controversial issues included in this edition were sequential single-agent versus simultaneous administration of combination chemotherapy, the role of combination chemotherapy in second-line treatment, the role of consolidation therapy, the role of anthracyclines in the treatment, and cost-effectiviness studies in ovarian cancer. Although the main topic of the symposium is advanced disease, this edition included the results of two parallel randomized studies (ACTION and ICON1) on the treatment of early disease. In addition, new trends in early detection of ovarian cancer have been updated. The pace of new agent development has increased, and it would be helpful to have more efficient preclinical models and early phase-clinical trials to guide the selection of active agents for phase III evaluation. Reaching international consensus is a challenge but offers the opportunity to test multiple regimens more efficiently against a single-control population, rather than conducting multiple smaller studies with redundant internal controls. If indeed answers to the relevant questions are to be obtained more quickly, then, a network of current national or international groups could potentially facilitate this.

show abstract

Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective

Cited by 2 publications

References 5 publications

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

Ovarian cancer treatment: what is new

Contact Info

Product

Resources

About